ClinicalTrials.gg
CompletedNCT06961643Updated Mar 2, 2026

Investigation of Pharmacokinetics and Safety of HRS-7535 in Subjects With Hepatic Impairment and Normal Hepatic Function

A Phase 1 interventional study of HRS-7535 Tables in Diabetes Mellitus, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Diabetes Mellitus by Jiangsu HengRui Medicine Co., Ltd. — 4 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
8th of 13
24 · median 30
Started
2025
the only one that year
Phase 1
13 of 13
4 open now
Registered
11th of 13
by date

Among the 13 studies in Diabetes Mellitus by Jiangsu HengRui Medicine Co., Ltd., this one is the 8th largest by enrollment, is the only one that started in 2025, is one of 13 in phase 1, and was the 11th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

4 of the 13 studies in Diabetes Mellitus by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Diabetes Mellitus by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The study is being conducted to compare the pharmacokinetics and safety of HRS-7535 in subjects with mild to moderate hepatic impairment and normal hepatic function.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand the study procedures and methods, participate voluntarily and be able to complete the study according to the protocol requirements, and sign the form (ICF) in writing.
  2. Aged 18-70 years old on the date of signing the ICF (including the threshold), both male and female.
  3. At the time of screening, male subjects weighing no less than 50 kg and female subjects weighing no less than 45 kg; (BMI): 18\~32 kg/m2 (including the threshold).

Exclusion criteria

Exclusion Criteria:

  1. In the judgment of the investigator, may be allergic to the study drug or its components.
  2. Smoking an average of more than 10 cigarettes per day within 3 months prior to screening.
  3. Alcoholics of within 3 months prior to screening, who consume more than 14 units of alcohol per week (1 unit=beer)360 mL of alcohol, or 45 mL of strong liquor with an alcohol content of 40%, or 150 mL of wine.
  4. History of drug or substance abuse, or a positive urine drug test at screening.
  5. Donated or lost ≥ 400 mL of blood within 3 months prior to screening.
  6. Individuals with a history of severe hypoglycemia.
  7. Undergone surgery within 6 months prior to screening, or plan to undergo surgery during the trial period.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Treatment group A

    Subjects with mild hepatic impairment.

    Drug: HRS-7535 Tables

  • Experimental
    Treatment group B

    Subjects with moderate hepatic impairment.

    Drug: HRS-7535 Tables

  • Experimental
    Treatment group C

    Subjects with normal hepatic function.

    Drug: HRS-7535 Tables

Interventions

06

What researchers measure

Primary outcomes

  1. The maximum plasma concentration of HRS-7535 (Cmax)

    Time frame: Post-dose at day 1 to day 4.

  2. Area under the concentration curve from time 0 to the last quantifiable concentration (AUC0-t)

    Time frame: Post-dose at day 1 to day 4.

  3. Area under the concentration curve from time 0 to extrapolated infinite time (AUC0-inf)

    Time frame: Post-dose at day 1 to day 4.

Secondary outcomes

  1. Time to maximum plasma concentration (Tmax)

    Time frame: Post-dose at day 1 to day 4.

  2. Terminal half-life (t1/2)

    Time frame: Post-dose at day 1 to day 4.

  3. Apparent clearance (CL/F)

    Time frame: Post-dose at day 1 to day 4.

  4. Apparent volume of distribution (Vz/F)

    Time frame: Post-dose at day 1 to day 4.

  5. Adverse events (AEs)

    Time frame: Screening period up to Day 7.

07

Study locations

1 site
  • Henan Provincial Infectious Disease Hospital
    Zhengzhou, Henan 450015, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Jan 2026, 7 months.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 7 months is above that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2025
First posted
May 8, 2025
StartActual
Jun 5, 2025
Primary completionActual
Jan 22, 2026
CompletionActual
Jan 22, 2026
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06961643
Responsible party
Sponsor
First posted
May 8, 2025
Start date
Jun 5, 2025
Primary completion
Jan 22, 2026
Completion
Jan 22, 2026
Last update
Mar 2, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-7535

Start the discussion